glp-1 vs glp PDB-101: Molecule of the Month: Receptor Agonists GLP-1 vs GLP-3: What's the

2.6% placebo) 63% of participants lost at least 5% 33% lost at least 10% Approximately 14% lost 15% or more What this means practically: For someone weighing 220 pounds: Average result: 18 pounds lost (reaching 202 pounds) Good responder: 22-33 pounds lost (reaching 187-198 pounds) Excellent responder (uncommon): 33+ pounds lost Ozempic/Wegovy (Semaglutide) Weight Loss Results Semaglutides effectiveness was established in the STEP trials: STEP 1 trial (semaglutide 2.4mg): Average weight loss: 14.9% of body weight at 68 weeks (vs

Kidney protection: the FLOW trial The FLOW trial studied semaglutide in patients with type 2 diabetes and chronic kidney disease

Recent research suggests that medications for type 2 diabetes of the GLP-1 class, such as Ozempic or Mounjaro, could offer an additional benefit beyond glycemic control: reduce the risk of dangerous blood clots in people with diabetes.This finding represents a new potential advantage for those who use these treatments

However, as more research is conducted and made public, attorneys will investigate and explore these potential injuries